An update on peptide-based therapies for type 2 diabetes and obesity

National Institute for Health and Care Excellence (NICE) guidance on heart valve disease

(2023) Benoy Nalin Shah   HEART

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

(2022) Mahmoud M. Ali et al.   BMC Endocrine Disorders

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

(2022) John J. Nestor et al.   Scientific Reports

Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective

(2022) Christophe De Block et al.   DIABETES OBESITY & METABOLISM

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

(2022) Nicolai J. Wewer Albrechtsen et al.   DIABETES OBESITY & METABOLISM

WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

(2022) Lawrence Blonde et al.   Endocrine Practice

Tirzepatide Once Weekly for the Treatment of Obesity

(2022) Ania M. Jastreboff et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

(2022) Hongwei Jiang et al.   Nature Communications

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

(2022) Tamer Coskun et al.   Cell Metabolism

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2022) Melanie J. Davies et al.   DIABETOLOGIA

Potential of a glucagon‐like peptide‐1 receptor /glucose‐dependent insulinotropic polypeptide receptor/ glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

(2022) Eiichi Araki et al.   Journal of Diabetes Investigation

Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists

(2022) Elena Jiménez-Martí et al.   Nutrients

Why are GLP-1 receptor agonists in short supply?

(2022) Clifford J. Bailey   British Journal of Diabetes

New perspectives in oral peptide delivery

(2021) Alessandra T. Zizzari et al.   DRUG DISCOVERY TODAY

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

(2021) Lone B Enebo et al.   LANCET

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

Development of Cagrilintide, a Long-Acting Amylin Analogue

(2021) Thomas Kruse et al.   JOURNAL OF MEDICINAL CHEMISTRY

Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing

(2021) Michael O. Frederick et al.   ORGANIC PROCESS RESEARCH & DEVELOPMENT

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

(2021) Martin Bossart et al.   Cell Metabolism

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

(2021) David C W Lau et al.   LANCET

The incretin/glucagon system as a target for pharmacotherapy of obesity

(2021) Stefano Del Prato et al.   Obesity Reviews

GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists

(2020) Jens Juul Holst et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?

(2020) Rebecca K. Vincent et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels

(2020) Christina Gar et al.   DIABETOLOGIA

The Discovery and Development of Liraglutide and Semaglutide

(2019) Lotte Bjerre Knudsen et al.   Frontiers in Endocrinology

Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist

(2019) Victoria E R Parker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

(2016) Matthias H. Tschöp et al.   Cell Metabolism

Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

(2016) Kristy Iglay et al.   CURRENT MEDICAL RESEARCH AND OPINION

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes

(2015) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

(2009) N. Irwin et al.   DIABETOLOGIA